NASDAQ:EVAX

Evaxion Biotech A/S Competitors

$6.98

+0.13 (+1.90 %)

(As of 04/20/2021 10:32 AM ET)

Add

Compare

Today's Range

$6.98

Now: $6.98▼

$6.98

50-Day Range

$5.20

MA: $6.68▼

$7.80

52-Week Range

$5.16

Now: $6.98▼

$10.34

Volume100 shs

Average Volume117,262 shs

Market Capitalization$134.01 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Evaxion Biotech A/S (NASDAQ:EVAX) Vs. IVA, SGTX, GMTX, LABP, TERN, and NEXI

Should you be buying EVAX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Evaxion Biotech A/S, including Inventiva (IVA), Sigilon Therapeutics (SGTX), Gemini Therapeutics (GMTX), Landos Biopharma (LABP), Terns Pharmaceuticals (TERN), and NexImmune (NEXI).

Evaxion Biotech A/S vs. Inventiva Stock

Evaxion Biotech A/S (NASDAQ:EVAX) and Inventiva (NYSE:IVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares Evaxion Biotech A/S and Inventiva's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion Biotech A/S	N/A	N/A	N/A	N/A	N/A
Inventiva	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Evaxion Biotech A/S and Inventiva, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion Biotech A/S	0	0	2	0	3.00
Inventiva	1	0	4	0	2.60

Evaxion Biotech A/S presently has a consensus target price of $18.00, suggesting a potential upside of 162.77%. Inventiva has a consensus target price of $27.3333, suggesting a potential upside of 104.13%. Given Evaxion Biotech A/S's stronger consensus rating and higher probable upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Inventiva.

Profitability

This table compares Evaxion Biotech A/S and Inventiva's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion Biotech A/S	N/A	N/A	N/A
Inventiva	N/A	N/A	N/A

Summary

Evaxion Biotech A/S beats Inventiva on 2 of the 3 factors compared between the two stocks.

Evaxion Biotech A/S vs. Sigilon Therapeutics Stock

Evaxion Biotech A/S (NASDAQ:EVAX) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares Evaxion Biotech A/S and Sigilon Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion Biotech A/S	N/A	N/A	N/A	N/A	N/A
Sigilon Therapeutics	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Evaxion Biotech A/S and Sigilon Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion Biotech A/S	0	0	2	0	3.00
Sigilon Therapeutics	0	1	3	0	2.75

Evaxion Biotech A/S presently has a consensus target price of $18.00, suggesting a potential upside of 162.77%. Sigilon Therapeutics has a consensus target price of $53.75, suggesting a potential upside of 251.31%. Given Sigilon Therapeutics' higher probable upside, analysts plainly believe Sigilon Therapeutics is more favorable than Evaxion Biotech A/S.

Profitability

This table compares Evaxion Biotech A/S and Sigilon Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion Biotech A/S	N/A	N/A	N/A
Sigilon Therapeutics	N/A	N/A	N/A

Summary

Sigilon Therapeutics beats Evaxion Biotech A/S on 2 of the 3 factors compared between the two stocks.

Evaxion Biotech A/S vs. Gemini Therapeutics Stock

Evaxion Biotech A/S (NASDAQ:EVAX) and Gemini Therapeutics (NASDAQ:GMTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares Evaxion Biotech A/S and Gemini Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion Biotech A/S	N/A	N/A	N/A	N/A	N/A
Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Evaxion Biotech A/S and Gemini Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion Biotech A/S	N/A	N/A	N/A
Gemini Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Evaxion Biotech A/S and Gemini Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion Biotech A/S	0	0	2	0	3.00
Gemini Therapeutics	0	0	4	0	3.00

Evaxion Biotech A/S presently has a consensus target price of $18.00, suggesting a potential upside of 162.77%. Gemini Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 96.08%. Given Evaxion Biotech A/S's higher probable upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Gemini Therapeutics.

Evaxion Biotech A/S vs. Landos Biopharma Stock

Evaxion Biotech A/S (NASDAQ:EVAX) and Landos Biopharma (NASDAQ:LABP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Profitability

This table compares Evaxion Biotech A/S and Landos Biopharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion Biotech A/S	N/A	N/A	N/A
Landos Biopharma	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and target prices for Evaxion Biotech A/S and Landos Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion Biotech A/S	0	0	2	0	3.00
Landos Biopharma	0	1	3	0	2.75

Evaxion Biotech A/S presently has a consensus target price of $18.00, suggesting a potential upside of 162.77%. Landos Biopharma has a consensus target price of $25.50, suggesting a potential upside of 142.17%. Given Evaxion Biotech A/S's stronger consensus rating and higher probable upside, equities analysts clearly believe Evaxion Biotech A/S is more favorable than Landos Biopharma.

Earnings and Valuation

This table compares Evaxion Biotech A/S and Landos Biopharma's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion Biotech A/S	N/A	N/A	N/A	N/A	N/A
Landos Biopharma	N/A	N/A	N/A	N/A	N/A

Summary

Evaxion Biotech A/S beats Landos Biopharma on 2 of the 3 factors compared between the two stocks.

Evaxion Biotech A/S vs. Terns Pharmaceuticals Stock

Terns Pharmaceuticals (NASDAQ:TERN) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Earnings and Valuation

This table compares Terns Pharmaceuticals and Evaxion Biotech A/S's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Evaxion Biotech A/S	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Terns Pharmaceuticals and Evaxion Biotech A/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Terns Pharmaceuticals	N/A	N/A	N/A
Evaxion Biotech A/S	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations for Terns Pharmaceuticals and Evaxion Biotech A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Terns Pharmaceuticals	0	0	3	0	3.00
Evaxion Biotech A/S	0	0	2	0	3.00

Terns Pharmaceuticals currently has a consensus price target of $30.50, suggesting a potential upside of 82.20%. Evaxion Biotech A/S has a consensus price target of $18.00, suggesting a potential upside of 162.77%. Given Evaxion Biotech A/S's higher possible upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Terns Pharmaceuticals.

Evaxion Biotech A/S vs. NexImmune Stock

NexImmune (NASDAQ:NEXI) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Profitability

This table compares NexImmune and Evaxion Biotech A/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NexImmune	N/A	N/A	N/A
Evaxion Biotech A/S	N/A	N/A	N/A

Earnings & Valuation

This table compares NexImmune and Evaxion Biotech A/S's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NexImmune	N/A	N/A	N/A	N/A	N/A
Evaxion Biotech A/S	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for NexImmune and Evaxion Biotech A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NexImmune	0	0	3	0	3.00
Evaxion Biotech A/S	0	0	2	0	3.00

NexImmune presently has a consensus target price of $33.3333, suggesting a potential upside of 81.55%. Evaxion Biotech A/S has a consensus target price of $18.00, suggesting a potential upside of 162.77%. Given Evaxion Biotech A/S's higher probable upside, analysts clearly believe Evaxion Biotech A/S is more favorable than NexImmune.